BDX Stock Forecast & Price Target

Becton Dickinson reported a robust financial performance in FQ3'25, with Medical Surgical Systems (MMS) generating $888 million in sales, reflecting a year-over-year increase of 5.3%, driven by strengths in Infusion Systems and growth in Dispensing Solutions and Pharmacy Automation. The company's MedTech business demonstrated consistent growth, exceeding 6% annually since the launch of BD 2025, alongside increasing margins, indicating effective strategic initiatives. Additionally, the Molecular Diagnostics Solutions (MDS) segment contributed significant revenue with FY24 sales of $4.43 billion, marking a 3.2% increase year-over-year, further solidifying the company's positive financial trajectory.

Becton Dickinson's organic revenue growth outlook has been revised downward from 4.0-4.5% to a range of 3.0-3.5%, reflecting ongoing challenges within its operational performance and decreased confidence in management's ability to forecast demand accurately. In its most recent quarter, the company's sales of $1.25 billion represented a 1.1% decline year-over-year, largely driven by low-single digit declines in key segments such as Biosciences and Diagnostic Solutions. Additionally, external factors, including procurement headwinds in China and reduced government research grants, further contributed to a challenging sales environment, particularly in the Bioscience sector, eroding growth prospects for the company.